Are there treatments for atypical parkinsonism? An update on actual options

Research output: Contribution to journalArticlepeer-review


Success in treating patients with atypical parkinsonism remains exceedingly low. It is particularly important for both neurologists and general practicians to have a guideline in the actual possible cure options. This study reviews the limited available literature reporting treatment trials about treatment in parkinsonism. Various therapeutical approaches have been tried with rasagiline, immunoglobulin, autologous mesenchymal stem cells, davunetide, lithium, and tideglusib. Recently, the transdermal rotigotine has been proposed for the treatment of atypical parkinsonism, as well as deep brain stimulation (DBS) of the peduncolopontine nucleus alone or combined with globus pallidus internus stimulation. The outcomes reviewed here highlight the need for the development of randomized, placebo-controlled trials to validate outcomes about rotigotine, DBS, and all other new therapies directed at altering the underlying biological mechanisms involved in the disease process.

Original languageEnglish
Pages (from-to)547-553
Number of pages7
JournalReviews in the Neurosciences
Issue number5
Publication statusPublished - Oct 1 2015


  • atypical parkinsonism
  • pharmacological intervention
  • treatment options

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Are there treatments for atypical parkinsonism? An update on actual options'. Together they form a unique fingerprint.

Cite this